The ATLAS-IT-05 trial is designed to assess the efficacy of LTX-315 in patients with advanced melanoma, who are refractory to treatment with anti-PD-1/PD-L1 inhibitors.
LTX-315 is being studied in combination with the immune checkpoint inhibitor pembrolizumab, which blocks tumor cells’ ability to prevent the body’s immune response. Results from earlier studies indicate that the combination of LTX-315 and pembrolizumab may work better than pembrolizumab alone.
The first patient in this trial was enrolled in December 2021, at MD Anderson Cancer Center in Houston, Texas - one of the world’s leading cancer hospitals.
Dr. Oystein Rekdal, CEO at Lytix Biopharma, said: “We are confident that Lytix’s unique technology offers a solution to today’s cancer treatment challenges, through the direct killing of cancer cells and a broad activation of the body’s own immune system. The results from the study will help us understand the contribution of LTX-315 to the clinical response among patients and help us to advance LTX-315 further towards the market."
The first interim results from the trial will be presented by Professor Stephane Dalle in a poster session at European Society for Medical Oncology (ESMO), taking place in Madrid, Spain, 20-24 October 2023.
Dr. Graeme Currie, chief data officer at Lytix, added: “We see a strong mechanistic rationale to explore the combination and treatment sequence of LTX-315 and an immune checkpoint inhibitor. Data from the ATLAS-IT-05 trial will help us understand the potential of LTX-315 to improve durability and response rates of patients treated in combination with existing immuno-oncology drugs. We look forward to presenting the first interim results of this trial at ESMO in October.”
